IRLAB Therapeutics (IRLAB) Q1 2025 earnings summary

Executive summary

• Achieved regulatory alignment with EMA and FDA for Phase III of mesdopetam, focusing on adult Parkinson's patients with levodopa-induced dyskinesias, and advanced clinical programs for pirepemat and IRL757.

• Five first-in-class candidates are in the pipeline, with three in clinical and two in preclinical stages, targeting various Parkinson's symptoms.

• Positive clinical results for pirepemat (clinically meaningful fall reduction in key subgroup) and IRL757 (favorable Phase I safety and absorption data); IRL757's next phase fully funded by MSRD/Otsuka and Michael J. Fox Foundation.

• Expanded patent protection for mesdopetam and pirepemat, extending exclusivity into the 2040s.

• Strengthened business development and increased awareness of the pipeline.

Financial highlights

• Cash and cash equivalents at quarter-end were SEK 89 million, with SEK 58 million as prepayments for the 757 study.

• Net sales were SEK 4.4 million, mainly related to the 757 program; operating loss improved to SEK -28.6 million from SEK -37.6 million year-over-year.

• Cash flow from operating activities was SEK 6.3 million, up from SEK -38.2 million year-over-year.

• Headcount stable at about 30–31 employees.

• Equity ratio fell to 3% (from 56% in Q1 2024), reflecting ongoing losses and reliance on debt.

Outlook and guidance

• Preparing for registration-enabling Phase III studies for mesdopetam, with design agreed by both FDA and EMA; ongoing business development to secure a partner.

• Pirepemat's next steps are under evaluation, with potential expansion into dementia and further analyses planned.

• IRL757 patient study in Parkinson's apathy to begin in H2 2025, fully funded by MSRD/Otsuka.

• IRL942 and IRL1117 preclinical programs progressing, with 1117 prioritized for IND-enabling studies; IRL942 development slowed.

• Focus remains on late-stage clinical assets and advancing preclinical programs with high potential.